Amgen and other competitors threaten Eli Lilly's weight loss drug dominance

Highlights

New competitors like Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim, and Zealand Pharma are challenging Eli Lilly's dominance in weight loss drugs.
Investors are now turning to Amgen in search of the next big obesity drug payout, causing a surge in Amgen's shares.
Eli Lilly and Novo Nordisk may face tough competition in the obesity drug market in the near future.

Opinions

You've reached the end